Alivus Life Sciences Limited — Updates, 01-08-2025: Press Release

Alivus Life Sciences reported Q1FY26 revenue of Rs. 601.8 Cr (+2.2% YoY), fueled by 14.5% growth in non-GPL business across key regions like India (Ex-GPL) and Europe. EBITDA rose 9.9% to Rs. 181.3 Cr, with margins at 30.1%. PAT stood at Rs. 121.5 Cr, and strong free cash flow of Rs. 100 Cr was generated. Management anticipates high single-digit revenue growth for FY26, with stronger H2 momentum and healthy 28-30% margins. Capacity expansion at Solapur (200 KL) and new product development are underway.